Biology subjects

Cho, S. C.

Publications and source records attributed to Cho, S. C..

3 recordsLinked to original sources

bioRxiv2026

Targeting Noncanonical TEAD Axis to Overcome DNA Repair-Driven Chemoresistance

How transcription factors contribute to DNA damage repair (DDR) independent of canonical gene regulation remains poorly understood. Here, we show that DNA double-strand break (DSB) triggers a functional state transition in TEAD, disengaging it from YAP-dependent transcription and translocating it to DNA lesions as a chromatin-associated DDR factor. Upon genotoxic stress, TEAD is rapidly recruited to damaged chromatin through a biphasic mechanism involving early poly(ADP-ribose)-dependent recruitment followed by ATM-driven {gamma}H2AX-mediated retention. At DNA lesions, TEAD constrains chromatin over-relaxation, suppresses excessive end resection, and promotes non-homologous end joining (NHEJ) independent of its canonical function. Conserved residues within the TEA domain mediate this noncanonical chromatin engagement of TEAD and define a druggable N-terminal interface. Pharmacological targeting of this interface impaired TEAD-dependent DSB repair and sensitized tumors to chemotherapy. Together, these findings establish noncanonical TEAD as a critical DNA repair factor and a clinically actionable driver of chemoresistance, while providing a conceptual framework for understanding how broader families of transcription factors may be repurposed as targetable DNA damage regulators in cancer.

cancer biology↗

bioRxiv2025

Nutrient availability dictates cancer metabolism-based therapeutic responses of non-oncology drugs

Metabolic deregulation is a major hallmark of cancer, therefore, interventions that modify tumor nutrient availability are considered attractive adjuvants for improving clinical outcomes for cancer patients. Much work remains, however, in clarifying how the nutritional status of each patient can affect the metabolic vulnerability of drugs and inform individual medication guidelines. Working toward the goal of oncometabolic precision medicine, we introduce CM-SLP (cancer metabolism-based synthetic lethality platform), a high-throughput screening platform that explores the metabolic vulnerability of non-oncology drugs induced by altered nutrient availability and predicts the potential synthetic lethal interactions with either hyper- or hypo-nutrient conditions. We present promising CM-SLP candidates, such as propafenone and biguanides, as representative non-oncology drugs that cooperatively enhance cytotoxicity via dysregulated metabolic pathways. Furthermore, identifying mTOR and Hippo pathways as mediators of combined propafenone/hypoglycemia or biguanides/hypoglycemia treatments, respectively, we were able to circumvent the need for dietary interventions by administering the mTOR or TEAD inhibitors to induce energy stress and cancer cell death. Together, CM-SLP represents a critical step toward integrating metabolic profiling into precision oncology, offering novel therapeutic avenues tailored to individual patient needs.

cancer biology↗

bioRxiv2023

Beclin1-Deficient Adipocytes Promote Tumor Progression by YAP/TAZ-dependent Adipocyte Transformation

Adipocytes are crucial components of the tumor microenvironment (TME) that play a prominent role in supporting tumor growth. However, the characteristics of cancer-associated adipocytes (CAAs) that contribute to the pro-tumorigenic niche remain to be fully established. Here, we used adipocyte-specific Beclin1 KO (BaKO) mice to investigate the role of maladaptive adipocytes in promoting tumor progression. BECN1-deficient adipocytes exhibited downregulation of adipogenic markers and activation of YAP/TAZ signaling, similar to the traits observed in CAAs. Thus, we generated adipocyte-specific Becn1/Yap1/Taz KO mice, which exhibit markedly restored phenotypes in adipose tissue, resulting in tumor regression compared to that in BaKO. Further, we observed dysregulation of the BECN1-YAP/TAZ axis in the adipose tissue of mice fed a high-fat diet (HFD). Treatment with the YAP/TAZ inhibitor, verteporfin, suppressed tumor progression in BaKO and HFD-fed mice, highlighting its efficacy against mice with metabolic dysregulation. Our findings provide insights into CAA formation and its significance in determining malignant TME, thereby suggesting a potential dual therapeutic strategy simultaneously targeting adipocyte homeostasis and cancer growth.

biochemistry↗